Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center Phase 2 Study of Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

NCT04326153 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT04326153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04326153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center Phase 2 Study of Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 20, 2020
Completion date
December 31, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iiia stage non-small cell lung cancer